First Report Managed Care

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Key Clinical Summary: Treatment selection for chronic myeloid leukemia in chronic phase (CML-CP) increasingly considers treatment goals, disease risk, comorbidities, toxicity, and cost rather than molecular response rates alone. The review supports dose reduction for patients with positive molecular responses who develop nonprohibitive tyrosine kinase inhibitor (TKI) toxicities, reserving treatment switches for prohibitive adverse events or resistance.

Key Takeaways: Portfolio diversification, strategic exit interest, and exposure to the pharmaceutical market are the main drivers of rising infusion investments as they allow investors to build diverse, strategic portfolios in the health care system. The value of infusion investments is influenced by the quality of revenue, the quality of earnings, and profit pool construction, all of which work together to drive transaction appeal for buyers.

Key Takeaways: In an analysis of 68 studies, Janus kinase (JAK) demonstrated improved efficacy for skin conditions such as atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hidradenitis suppurativa. Patients treated with JAK inhibitors had higher response rates than patients who received a placebo. JAK inhibitors demonstrated similar safety profiles between drugs, with only a slight increase in toxicity compared to placebo.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Key Takeaways The Centers for Medicare & Medicaid Services (CMS) and US Food and Drug Administration (FDA) have proposed the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway that would coordinate evidence requirements earlier in device development, potentially accelerating Medicare coverage for eligible FDA-designated Breakthrough Devices.

Key Takeaways: Omalizumab improved patient tolerance: In total, 193 two-dose initiation challenges took place during the study, with patients having tolerance for 181 (94%) challenges after receiving omalizumab pretreatment. Omalizumab streamlined oral immunotherapy (OIT) protocols: Traditional OIT procedures include multistep dose escalations, but the majority of patients began OIT at target maintenance dosing.

Key Takeaways: Historically, topical corticosteroids (TCS) have been used as first-line treatments for pediatric skin conditions, although they have a higher risk of side effects for children. Ongoing research in pediatric dermatology is focused on the impact of nonsteroidal topical therapies (NSTTs) on conditions such as atopic dermatitis (AD), psoriasis, alopecia areata (AA), vitiligo, and seborrheic dermatitis (SD).